These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 2123072)

  • 1. Usefulness of late coronary thrombolysis (recombinant tissue-type plasminogen activator) in preserving left ventricular function in acute myocardial infarction.
    Villari B; Piscione F; Bonaduce D; Golino P; Lanzillo T; Condorelli M; Chiariello M
    Am J Cardiol; 1990 Dec; 66(19):1281-6. PubMed ID: 2123072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of late administration of tissue-type plasminogen activator on left ventricular remodeling and function after myocardial infarction.
    Bonaduce D; Petretta M; Villari B; Breglio R; Conforti G; Montemurro MV; Lanzillo T; Morgano G
    J Am Coll Cardiol; 1990 Dec; 16(7):1561-8. PubMed ID: 2123907
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anistreplase versus alteplase in acute myocardial infarction: comparative effects on left ventricular function, morbidity and 1-day coronary artery patency. The TEAM-3 Investigators.
    Anderson JL; Becker LC; Sorensen SG; Karagounis LA; Browne KF; Shah PK; Morris DC; Fintel DJ; Mueller HS; Ross AM
    J Am Coll Cardiol; 1992 Oct; 20(4):753-66. PubMed ID: 1527286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. More rapid, complete, and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction. RAPID Investigators.
    Smalling RW; Bode C; Kalbfleisch J; Sen S; Limbourg P; Forycki F; Habib G; Feldman R; Hohnloser S; Seals A
    Circulation; 1995 Jun; 91(11):2725-32. PubMed ID: 7758177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Coronary patency, infarct size and left ventricular function after thrombolytic therapy for acute myocardial infarction: results from the tissue plasminogen activator: Toronto (TPAT) placebo-controlled trial. TPAT Study Group.
    Morgan CD; Roberts RS; Haq A; Baigrie RS; Daly PA; Gent M; Armstrong PW
    J Am Coll Cardiol; 1991 Jun; 17(7):1451-7. PubMed ID: 1903404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction.
    GUSTO Angiographic Investigators
    N Engl J Med; 1993 Nov; 329(22):1615-22. PubMed ID: 8232430
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thrombolysis and coronary occlusion: effects upon the non-infarct zone.
    Cranswick R; Carter G; Wilkes N; Nelson G
    Eur Heart J; 1992 Jun; 13(6):770-5. PubMed ID: 1623865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Significance of a coronary artery with thrombolysis in myocardial infarction grade 2 flow "patency" (outcome in the thrombolysis and angioplasty in myocardial infarction trials). Thrombolysis and Angioplasty in Myocardial Infarction Study Group.
    Lincoff AM; Topol EJ; Califf RM; Sigmon KN; Lee KL; Ohman EM; Rosenschein U; Ellis SG
    Am J Cardiol; 1995 May; 75(14):871-6. PubMed ID: 7732992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coronary thrombolysis with recombinant tissue-type plasminogen activator: patency rate and regional wall motion after 3 months.
    Jang IK; Vanhaecke J; De Geest H; Verstraete M; Collen D; Van de Werf F
    J Am Coll Cardiol; 1986 Dec; 8(6):1455-60. PubMed ID: 3097099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early T wave inversion after thrombolytic therapy predicts better coronary perfusion: clinical and angiographic study.
    Matetzky S; Barabash GI; Shahar A; Rabinowitz B; Rath S; Zahav YH; Agranat O; Kaplinsky E; Hod H
    J Am Coll Cardiol; 1994 Aug; 24(2):378-83. PubMed ID: 8034871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative effects of APSAC and rt-PA on infarct size and left ventricular function in acute myocardial infarction. A multicenter randomized study.
    Bassand JP; Cassagnes J; Machecourt J; Lusson JR; Anguenot T; Wolf JE; Maublant J; Bertrand B; Schiele F
    Circulation; 1991 Sep; 84(3):1107-17. PubMed ID: 1909218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased left ventricular dysfunction in elderly patients despite successful thrombolysis: the GUSTO-I angiographic experience.
    Lesnefsky EJ; Lundergan CF; Hodgson JM; Nair R; Reiner JS; Greenhouse SW; Califf RM; Ross AM
    J Am Coll Cardiol; 1996 Aug; 28(2):331-7. PubMed ID: 8800106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative radionuclide assessment of regional ventricular function after thrombolytic therapy for acute myocardial infarction: results of phase I Thrombolysis in Myocardial Infarction (TIMI) trial.
    Wackers FJ; Terrin ML; Kayden DS; Knatterud G; Forman S; Braunwald E; Zaret BL
    J Am Coll Cardiol; 1989 Apr; 13(5):998-1005. PubMed ID: 2494246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined tissue-type plasminogen activator and prostacyclin therapy for acute myocardial infarction. Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 4 Study Group.
    Topol EJ; Ellis SG; Califf RM; George BS; Stump DC; Bates ER; Nabel EG; Walton JA; Candela RJ; Lee KL
    J Am Coll Cardiol; 1989 Oct; 14(4):877-84. PubMed ID: 2477426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the effects of streptokinase and tissue plasminogen activator on regional wall motion after first myocardial infarction: analysis by the centerline method with correction for area at risk.
    Cross DB; Ashton NG; Norris RM; White HD
    J Am Coll Cardiol; 1991 Apr; 17(5):1039-46. PubMed ID: 1901072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Accelerated plasminogen activator dose regimens for coronary thrombolysis. The TAMI-7 Study Group.
    Wall TC; Califf RM; George BS; Ellis SG; Samaha JK; Kereiakes DJ; Worley SJ; Sigmon K; Topol EJ
    J Am Coll Cardiol; 1992 Mar; 19(3):482-9. PubMed ID: 1537998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of time required for reperfusion (thrombolysis or angioplasty, or both) and location of acute myocardial infarction on left ventricular functional reserve capacity several months later.
    Little T; Crenshaw M; Liberman HA; Battey LL; Warner R; Churchwell AL; Eisner RL; Morris DC; Patterson RE
    Am J Cardiol; 1991 Apr; 67(9):797-805. PubMed ID: 1901437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiographic findings and outcome in diabetic patients treated with thrombolytic therapy for acute myocardial infarction: the GUSTO-I experience.
    Woodfield SL; Lundergan CF; Reiner JS; Greenhouse SW; Thompson MA; Rohrbeck SC; Deychak Y; Simoons ML; Califf RM; Topol EJ; Ross AM
    J Am Coll Cardiol; 1996 Dec; 28(7):1661-9. PubMed ID: 8962549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A difference between front-loaded streptokinase and standard-dose recombinant tissue-type plasminogen activator in preserving left ventricular function after acute myocardial infarction (the Central Illinois Thrombolytic Therapy Study).
    Taylor GJ; Moses HW; Koester D; Colliver JA; Katholi RE; Dove JT; Woodruff RC; Mikell FL; Becker LC; Sheehan FH
    Am J Cardiol; 1993 Nov; 72(14):1010-4. PubMed ID: 8213579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new thrombolytic regimen for acute myocardial infarction using combination half dose tissue-type plasminogen activator with full dose streptokinase: a pilot study. KAMIT Study Group.
    Grines CL; Nissen SE; Booth DC; Branco MC; Gurley JC; Bennett KA; DeMaria AN
    J Am Coll Cardiol; 1989 Sep; 14(3):573-80. PubMed ID: 2504797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.